1155662-43-3

Basic information

• Product Name: (R)-3-methoxycarbonyl-(R)-5-methylpiperidine
• CAS NO: 1155662-43-3
• Molecular Weight: 157.213
• Mol File: 1155662-43-3.mol
• Article Data: 11

Chemical Properties

• CAS DataBase Reference: (R)-3-methoxycarbonyl-(R)-5-methylpiperidine(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-3-methoxycarbonyl-(R)-5-methylpiperidine(1155662-43-3)
• EPA Substance Registry System: (R)-3-methoxycarbonyl-(R)-5-methylpiperidine(1155662-43-3)

Safety Data

• Hazardous Substances Data: 1155662-43-3(Hazardous Substances Data)

Usage

General Description

(R)-3-methoxycarbonyl-(R)-5-methylpiperidine is a chemical compound that belongs to the class of piperidine alkaloids. It is a chiral molecule, meaning it has a non-superimposable mirror image, and the (R) prefix indicates the absolute configuration of the molecule. (R)-3-methoxycarbonyl-(R)-5-methylpiperidine is commonly used in the pharmaceutical industry for the synthesis of various drugs, including antiviral and antimalarial agents. Its structure and properties make it a valuable building block for the creation of new drug candidates. Additionally, (R)-3-methoxycarbonyl-(R)-5-methylpiperidine has demonstrated potential pharmacological activities, making it an interesting target for further research and development.

Upstream product

• 29681-45-6 5-methylnicotinic acid methyl ester 
• 29681-44-5 5-bromo-3-pyridine carboxylic acid methyl ester 
• 3222-49-9 5-methylnicotinic acid 

Downstream Products

• 1365887-45-1 1-(tert-butoxycarbonyl)-5-methylpiperidine-3-carboxylic acid 

Relevant articles and documents

Continuous flow hydrogenation of functionalized pyridines

The heterogeneous hydrogenation of substituted pyridines has been accomplished by employing a continuous flow hydrogenation device that incorporates in situ hydrogen generation by electrolysis of H20 and pre-packed catalyst cartridges. In general, the hydrogenation reactions proceeded smoothly regardless of the supported precious metal catalyst (Pd/C, Pt/C, or Rh/C). By using 30-80 bar of hydrogen pressure at 60-80 °C full conversion was typically achieved in all cases at a flow rate of 0.5 mL min -1, providing the corresponding piperidines in high yields. For disubstituted pyr idines, variations in stereoselectivity were observed depending on both the metal catalyst and the temperature/ pressure of the hydrogenation reaction. For ethyl nicotinate the selectivity between partial and full hydrogenation could be tuned depending on the hydrogen pressure, solvent, and the choice of supported metal catalyst. Changing the hydrogen source from H20 to D2C) allowed the preparation of de-uteriated derivatives. Wiley-VCH Verlag GmbH & Co. KGaA.

FUSED PYRAZOLE DERIVATIVES AS NOVEL ERK INHIBITORS

Disclosed are the ERK inhibitors of Formula (I): (Formula (I)) and the pharmaceutically acceptable salts thereof. All substitutents are as defined herein. Also disclosed are methods of treating cancer using the compounds of Formula (I).

N-ACYL PYRIMIDINE BIARYL COMPOUNDS AS PROTEIN KINASE INHIBITORS

The present invention provides a compound of the general formula (1): wherein one of X and Y is N and the other is an optionally substituted carbon atom, and Z2-Z5 represent one or two nitrogen atoms, as further described herein, including pharmaceutically acceptable salts, enantiomers, stereoisomers, rotamers, tautomers, diastereomers, or racemates thereof. These compounds inhibit the activity of CDK9 and are thus useful as pharmaceuticals and as components of pharmaceutical compositions. Also provided are methods of treating a disease or condition mediated by CDK9 using the compounds described herein or pharmaceutical compositions comprising such compounds.